-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
-
Summary
-
Halozyme Therapeutics, Inc. quarterly/annual Operating Lease, Payments history and growth rate from 2018 to 2023.
- Halozyme Therapeutics, Inc. Operating Lease, Payments for the quarter ending June 30, 2024 was $1.7M, unchanged year-over-year.
- Halozyme Therapeutics, Inc. Operating Lease, Payments for the twelve months ending June 30, 2024 was $6.8M, a 13.3% increase year-over-year.
- Halozyme Therapeutics, Inc. annual Operating Lease, Payments for 2023 was $6.7M, a 59.5% increase from 2022.
- Halozyme Therapeutics, Inc. annual Operating Lease, Payments for 2022 was $4.2M, a 55.6% increase from 2021.
- Halozyme Therapeutics, Inc. annual Operating Lease, Payments for 2021 was $2.7M, a 15.6% decline from 2020.
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)